SL327 (SL-327) is a novel, potent and selective inhibitor for MEK1/2 with the ability to cross blood brain barrier and block fear conditioning.

U0126 (also known as U0126-EtOH) is a novel potent, highly selective and non-ATP competitive inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays.

APS-2-79 HCl (APS279 HCl; APS-279), the hydrochloride salt of APS-2-79, is an antagonist of MAPK (mitogen-activated protein kinase) with anticancer effects.

Honokiol (also known as NSC 293100) is a naturally-occuring, bioactive, biphenolic phytochemical and an active ingredient of magnolia extract with potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities.

GDC-0623 (G868) is a novel, potent, orally bioactive, selective and non-ATP-competitive (allosteric) inhibitor of MEK1 with potential anticancer activity.

Cobimetinib hemifumarate (formerly also known as RG7420; XL518; GDC0973), the hemifumarate salt of cobimetinib, is an oral, highly potent and selective MEK1 inhibitor with potential antineoplastic activity.

PD98059 is a novel flavanoid acting as a selective, reversible, and non-ATP competitive MEK inhibitor with potential anti-inflammatory and anticancer activity.

Refametinib (formerly RDEA-119, BAY 86-9766) is an orally bioavailable, highly selective and non-ATP-competitive (allosteric) inhibitor of MEK1/2 with potential antitumor activity.

Binimetinib (trade name: Mektovi; formerly ARRY-438162; ARRY-162; MEK-162) is a highly selective and orally bioavailable MEK1/2 (mitogen-activated protein kinase kinase) inhibitor with potential antineoplastic activity.

Selumetinib sulfate (also known as AZD6244 sulfate; ARRY-142886 sulfate) is a novel, potent, highly selective, orally bioavailable, and non-ATP-competitive small molecule MEK1 inhibitor with IC50 of 14 nM in cell-free assays and with anticancer activity, it also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc.